Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
about
The biology of cytomegalovirus drug resistanceGanciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasmaBrincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection.Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with CytomegalovirusPhenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations.Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens.
P2860
Q35684511-666A3515-8426-4F40-8519-0D5A7C1C9B78Q35943076-D641C08F-4878-47DE-9DD2-6F9CF261EA2EQ36324846-4FDAAE51-7826-4512-9525-ECB3CA7E98FDQ37242897-9310646C-0864-46E7-A073-C69EA4B7DF37Q37671946-C8370402-9D02-4C83-B673-C7A3E5759470Q38324789-A7BB0513-98DF-433E-A122-831179439518Q38779846-DAC68A0F-4491-4BB4-9969-B17D236F9532Q39949115-611C7853-91FE-413F-987D-E01CFD5A6FE6Q40325104-398D98FE-5CEA-4C58-BCE1-CE1ACFF1AE09Q40414645-6BDB75B0-3419-441E-90AE-3410FB30D6EBQ40483485-35A403C1-92F6-4B70-93B1-4B3A29C82C68Q40728808-FFCF8C5C-8EDB-481C-9BF4-253CF4667D78Q41060769-65F8FD26-AE1D-43B3-9FD6-B2B01BAF90B1Q41657330-BEFA1B54-B667-40B7-8D96-9093AD6AAAC2Q41858999-A0F8FBBC-9CA8-4BC1-8354-31CBA7842BD4Q43644735-9C87D8B4-6275-4083-A48A-92E909D67B73
P2860
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@ast
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@en
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@nl
type
label
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@ast
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@en
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@nl
prefLabel
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@ast
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@en
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@nl
P2860
P1476
Phenotypic diversity of cytome ...... erved after antiviral therapy.
@en
P2093
Sunwen Chou
P2860
P304
P356
10.1016/J.JCV.2011.01.004
P577
2011-02-03T00:00:00Z